Aniridia

Lore & Background

Aniridia may be broadly divided into hereditary and sporadic forms. Hereditary aniridia is usually transmitted in an autosomal dominant manner, although rare autosomal recessive forms such as Gillespie syndrome have also been reported. Sporadic aniridia mutations may affect the WT1 region adjacent to the AN2 aniridia region, causing a kidney cancer called nephroblastoma (Wilms tumor). These patients often also have genitourinary abnormalities and intellectual disability (WAGR syndrome). Several different mutations may affect the PAX6 gene, with some mutations inhibiting gene function more than others, leading to variability in disease severity. Some aniridic individuals are only missing a relatively small amount of iris, do not have foveal hypoplasia, and retain relatively normal vision.

Reader's Guide

The PAX6 gene, located within the AN2 region on the short arm of chromosome 11 (11p13), plays a crucial role in the development of the eye and other structures. Defects in the PAX6 gene cause aniridia-like ocular defects in mice and Drosophila. Aniridia is a heterozygous disorder; when both copies are altered, the result is a uniformly fatal condition with near complete failure of entire eye formation. In 2001, two cases of homozygous aniridia patients were reported; the fetuses died prior to birth and had severe brain damage. Molecular testing for PAX6 gene mutations is available for isolated aniridia and Gillespie syndrome. For WAGR syndrome, high-resolution cytogenetic analysis and FISH can identify deletions within chromosome band 11p13. In May 2018, the U.S. Food and Drug Administration approved the CustomFlex Artificial Iris, the first synthetic iris for use in adults and children with congenital aniridia or iris defects related to other conditions.

Did You Know?

• Aniridia can be congenital, typically affecting both eyes, or caused by a penetrant injury.
• The PAX6 gene shares approximately 95% similarity with the pax gene found in zebrafish.
• When both copies of the PAX6 gene are altered (homozygous condition), the result is a uniformly fatal condition with near complete failure of entire eye formation.

The PAX6 Gene: A Deeply Conserved Architect of Vision

The PAX6 gene, situated on the short arm of chromosome 11 within the AN2 region, serves as a master regulator of eye development. Its name derives from the PAired boX DNA-binding sequence it contains, and it orchestrates a cascade of downstream genetic events necessary for forming the eye and related structures. What makes PAX6 particularly striking is its extraordinary evolutionary conservation: the human version shares roughly 95 percent sequence identity with the pax gene in zebrafish, a fish lineage that split from the vertebrate line approximately 400 million years ago. This near-identical code across such vast evolutionary distance underscores how fundamental this gene is to ocular development. In animal models, disrupting PAX6 in mice or fruit flies produces aniridia-like eye defects. In humans, the condition is heterozygous—only one of the two chromosome 11 copies carries the mutation. When both copies are compromised, the outcome is uniformly lethal: two homozygous cases documented in 2001 resulted in fetal death before birth accompanied by severe brain damage, and homozygous mutations in mice produce complete loss of eyes and nose along with catastrophic neural injury.

A Condition Far Beyond a Missing Iris

Although aniridia is most recognizable for the absence or near-absence of the iris—leaving the central eye appearing predominantly black—it is in reality a far more complex developmental disorder. The iris normally functions as a muscular ring that modulates pupil size and controls light entry, but congenital aniridia extends well beyond this single structure. Affected eyes frequently exhibit macular hypoplasia, optic nerve underdevelopment, corneal abnormalities, and cataract formation. Vision can be severely compromised, and the condition is commonly accompanied by nystagmus, amblyopia, strabismus, buphthalmos, and heightened light sensitivity. The disorder may arise congenitally, typically involving both eyes, or result from a penetrating injury. In some patients, aniridia is embedded within a broader genetic syndrome. WAGR syndrome pairs the ocular findings with kidney nephroblastoma, genitourinary anomalies, and intellectual disability. Gillespie syndrome links aniridia with cerebellar ataxia. These syndromic associations reveal that the underlying genetic disruption affects multiple organ systems, not just the eye.

Inheritance Patterns and a Wide Phenotypic Spectrum

Aniridia can be transmitted hereditarily or arise sporadically. The hereditary form most often follows an autosomal dominant pattern, meaning each child of an affected parent carries a fifty-percent risk of inheriting the mutation. Rare autosomal recessive variants, such as those seen in Gillespie syndrome, have also been documented. Sporadic cases may involve mutations in the WT1 region adjacent to the AN2 aniridia locus on chromosome 11p13, predisposing patients to nephroblastoma and the broader WAGR syndrome. Within the PAX6 gene itself, multiple distinct mutations have been identified, and they do not all carry equal weight. Some variants suppress gene function more aggressively than others, producing a wide spectrum of clinical severity. At the milder end, an affected individual may be missing only a small portion of iris tissue, lack foveal hypoplasia, and retain relatively functional vision. These milder presentations are thought to reflect a degree of residual gene activity—what researchers term heterozygous insufficiency—where enough PAX6 function remains to prevent the most devastating ocular and systemic consequences.

From Genetic Testing to a Custom-Built Iris

Diagnosing aniridia and its associated syndromes relies on a combination of molecular and cytogenetic tools. For isolated aniridia and Gillespie syndrome, DNA sequencing of the entire PAX6 coding region along with deletion and duplication analysis can pinpoint the responsible mutation. In WAGR syndrome, where the WT1 gene sits alongside PAX6 on chromosome band 11p13, high-resolution cytogenetic analysis and fluorescence in situ hybridization are employed to detect deletions spanning both loci. On the treatment front, a significant milestone arrived in May 2018 when the U.S. Food and Drug Administration cleared the CustomFlex Artificial Iris—the first synthetic iris approved for both adults and children. Designed for patients with congenital aniridia or iris loss due to albinism, traumatic injury, or surgical removal following ocular melanoma, the device is crafted from thin, foldable, medical-grade silicone. Each implant is custom-sized and colored to match the individual patient, then surgically positioned and secured either by the eye's own anatomical structures or, when necessary, by sutures.

Gallery